ReviewRheumatology (Oxford, England)2015
Indications for IVIG in rheumatic diseases.
Review in Rheumatology (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 79 citations in OpenAlex.
- Successful corticosteroid-free management of anti-HMG-CoA reductase immune-mediated necrotizing myopathy with subcutaneous immunoglobulins monotherapy: a case report.Journal of medical case reports · 2026Article
- Management of hypogammaglobulinemia in pediatric patients with refractory lupus nephritis: a focus on belimumab.Frontiers in pediatrics · 2026Article
- Susac syndrome - different treatment approaches for one disease (analysis of case series).Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- The B-cells paradigm in systemic sclerosis: an update on pathophysiology and B-cell-targeted therapies.Clinical and experimental immunology · 2025Review
- Neuropsychiatric Systemic Lupus Erythematosus: Molecules Involved in Its Imunopathogenesis, Clinical Features, and Treatment.Molecules (Basel, Switzerland) · 2024Review
- A Challenging Inflammatory Myopathy Case-Report: Dermatomyositis-Like Rash in an Anti-HMGCR Positive Patient with an Uncertain Muscle Histology.Mediterranean journal of rheumatology · 2023Article
- Intravenous immunoglobulin therapy in immunoglobulin A vasculitis with gastrointestinal tract involvement.Clinical and experimental medicine · 2023Article
- Article
- Production of recombinant human IgG1 Fc with beneficial N-glycosylation pattern for anti-inflammatory activity using genome-edited chickens.Communications biology · 2023Article
- Dilemma of immunosuppression and infection risk in systemic lupus erythematosus.Rheumatology (Oxford, England) · 2023Article
- Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine.Antibodies (Basel, Switzerland) · 2023Review
- Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance.Frontiers in immunology · 2023Review
- Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis.Biomedicines · 2022Review
- Case Report: Guillain-Barré Syndrome as Primary Presentation of Systemic Lupus Erythematosus (SLE-GBS) in a Teenage Girl.Frontiers in pediatrics · 2022Article
- A Rare Case of Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of Unknown Primary Origin.The American journal of case reports · 2021Article
- IVIG ameliorate inflammation in collagen-induced arthritis: projection for IVIG therapy in rheumatoid arthritis.Clinical and experimental immunology · 2021Article
- Biologic Therapy in COVID-19.Archivos de bronconeumologia · 2021Article
- COPD in Spain at the Start of a New Decade.Archivos de bronconeumologia · 2021Article
- Autoimmunity as the comet tail of COVID-19 pandemic.World journal of clinical cases · 2020Review
- High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The use of IVIG to treat a wide variety of immune-driven diseases has grown rapidly, although the mechanism of action is not completely understood. Increasing demand for IVIG coupled with concerns regarding potential transmissible agents has led to worldwide supply shortages. National agencies have therefore produced guidelines for its use, with the latest England and Wales guideline being published in 2011. Due to the rarity of the rheumatic diseases, the evidence for IVIG use has been shown to be lacking in some areas and promising in others. Conditions in which IVIG has been shown to have benefit include ITP, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy occurring in the context of rheumatic disease, as well as in SLE, idiopathic inflammatory myopathies and ANCA-associated vasculitides. This review looks at current IVIG use and is designed to be an aid for rheumatologists when considering the use of IVIG in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.